The Key Biomarkers Changing How and When We Diagnose Alzheimer’s Disease
Innovations in biomarker science, particularly in cerebrospinal fluid (CSF) and blood, are expanding Alzheimer’s testing beyond specialty care.
presented by
How Real-World Data Is Reshaping the NSCLC Patient Journey
A new eBook, sponsored by PurpleLab, examines how a significant number of patients with non-small cell lung cancer miss out on optimal care due to gaps in biomarker testing, socioeconomic barriers, incomplete patient journey data, and what can be done to change that.
presented by
Survey on the Healthcare Financial Landscape Offers a Roadmap for Stakeholders
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
presented by
Using Real World Data from the Patient Experience to Improve Drug Development
A new eBook published by MedCity News for PurpleLab highlights how RWD and SDOH can lead to more inclusive clinical trials and drugs that improve the quality of life for larger, diverse patient populations not only for NSCLC, but other conditions as well.
Broadening Biomarker Validation for Alzheimer’s Disease Diagnosis Globally
Demonstrating the clinical utility and cost-effectiveness of innovative blood-based biomarker tests can help pave the way for making timely AD diagnosis and proactive care the norm.
Taking The Wheel: A Proactive Approach to Improving Longevity
When you equip patients with a deeper understanding of their bodies, they are better prepared to act on medical advice.
Why Blood is Best: Transforming the Diagnostic Journey for Alzheimer’s Disease
As the pool of approved therapies continues to (hopefully) expand, the clinical and diagnostic testing communities need to do a better job at ensuring the right patients move through this journey more quickly – and accurately – to improve their health and prognosis.
Beyond Analytics: How Sellers Dorsey is Hard-Coding Value into Medicaid Policy [Video]
How to turn analytics into actual policy outcomes.
Closing the Gap: Advancing Precision Oncology Through Education and Collaboration
How top-to-bottom collaboration can alleviate hurdles and help increase equitable access to the most effective treatments for all cancer patients.
Eliminating Barriers and Increasing Access to New Testing to Improve Prenatal Care
New advancements can only be fully realized when clinicians, lawmakers, and patients come together. Biomarker tests not only have the potential to improve patient outcomes and address health equity, they can also decrease expenses for financially vulnerable medical systems.
What are the 4 Pillars of Cancer Care?
Although the definition is evolving, truly personalized cancer care might be thought of as having four major pillars: interrogation of the cancer, predictive testing, inherited genes, and patient lifestyle, values and goals.
Legislative victories fuel advocates for coverage of biomarker testing
Lawmakers have acted to strengthen insurance reimbursement for biomarker testing in California, Illinois and Louisiana. Patient advocates and testing companies hope more will act in the coming year.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.